Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study

Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study

Background This real-world study compared the safety and effectiveness of Dolutegravir/lamivudine (D/L) and Bictegravir/Emtricitabine/Tenefovir alafenamide (B/F/T) switch therapy regimens for people living with HIV (PLWH) Methods The retrospective study conducted from April 2019 to November 2022, in...

Full description

Bibliographic Details
Main Authors: Hernando Knobel, Esperanza Cañas-Ruano, Ana Guelar, Pablo Knobel, Judit Villar-García, Alicia González-Mena, Ceclia Canepa, Itziar Arrieta-Aldea, Augustin Marcos, Agustí Abalat-Torrres, Roberto Güerri-Fernández
Format: Article
Language:English
Published: Taylor & Francis Group 2023-07-01
Series:HIV Research & Clinical Practice
Subjects:
switching antiretroviral therapy
optimizing antiretroviral therapy
dolutegravir/lamivudine
bictegravir/emtricitabine/tenofovir alafenamide
real-world data
Online Access:http://dx.doi.org/10.1080/25787489.2023.2239564

Internet

http://dx.doi.org/10.1080/25787489.2023.2239564

Similar Items